Abstract
Evaluation of the prevalence of benign prostatic hyperplasia (BPH) worldwide and its social and economic as well as treatment implications has been hampered by a lack of consensus regarding a working definition for the disease. Linguistic and cultural validation of the International Prostate Symptom Score (I-PSS) has brought the ideal of representing the same symptom burden across different populations closer to reality. A recent opportunity to validate the I-PSS and to analyze BPH incidence in Russia has expanded these evaluations beyond the previous geographic boundaries of North America, Japan and Western Europe. Additionally, the concurrence of BPH and hypertension in many older men raises new questions of association between the two disease entities, and the possibilities of cross-screening and combined treatment for the two disorders. A pilot study now being conducted in Portugal represents the first population-based examination of this possible association between BPH and hypertension.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
